



**University of
Zurich^{UZH}**

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2005

ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML)

Simonsson, B ; Kloke, O ; Stahel, R A

DOI: <https://doi.org/10.1093/annonc/mdi807>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-155131>

Journal Article

Published Version

Originally published at:

Simonsson, B; Kloke, O; Stahel, R A (2005). ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML). *Annals of Oncology*, 16(suppl_1) : i52 – i53.

DOI: <https://doi.org/10.1093/annonc/mdi807>

ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML)

Incidence

- The incidence according to the SEER data is 1.38/100 000 per year. The mortality is 0.74/100 000 per year. The median age at diagnosis is around 60 years.

Diagnosis

- Myeloid hyperplasia associated with splenomegaly and neutrophil leukocytosis, thrombocytosis and basophilia are typical features of CML in its initial chronic phase.
- In almost all patients, blood and marrow cells carry the specific chromosomal translocation t(9;22), the Philadelphia chromosome, or its variants.

Staging and risk assessment

- The major risk is the transformation of the initial chronic into the blastic phase of the disease characterized by $\geq 30\%$ blasts in blood or marrow, or $\geq 50\%$ blasts and promyelocytes in marrow, or extra-medullary blastic infiltration. An accelerated phase (transitional from chronic to blastic phase) is defined as 15–29% blasts in marrow or blood, or 30–49% blasts plus promyelocytes in marrow.
- Prognostic scores based on age, spleen size, and blood cell counts have been developed that allow the discrimination of patient subgroups with different prognosis on cytoreductive chemotherapy and on interferon, respectively.

Treatment

- The only curative treatment available is allogeneic stem cell transplantation. Younger patients, especially those with unfavorable risk factors, should be considered for this treatment at diagnosis. The patient should be involved in the decision process, which must balance the chance of cure against the risk of transplant-related mortality.
- The tyrosine kinase inhibitor imatinib is highly effective in inducing hematologic and cytogenetic remissions [I, A]. Imatinib (400 mg p.o. daily) is first-line standard therapy because of better tolerance, a much higher cytogenetic response rate, and a lower progression rate to accelerated or blastic phase compared with interferon-/ara-C-based therapy. However, its long term efficacy is not yet known [I, A].
- In good prognosis patients, interferon- α at doses of 3–5 MU/m² daily may be considered as an alternative treatment.

- The clinical benefit of intensive chemotherapy with or without autologous stem cell transplantation is not proven.
- If the treatment goal is only to relieve symptoms, hydroxyurea may be considered [II, A].

Follow-up

- Patients are followed by blood cell counts once weekly during the first weeks of therapy and every 1–2 months later on. Bone marrow cytogenetics (and/or quantitative PCR of bcr/abl) should be performed in imatinib-treated or interferon-treated patients every 6 months. Patients relapsing after allotransplant may still have curative options, e.g. donor lymphocyte transfusions, and require more frequent controls.

Note

Levels of Evidence [I–V] and Grades of Recommendation [A–D] as used by the American Society of Clinical Oncology are given in square brackets. Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty.

Literature

1. Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in “good risk” chronic granulocytic leukaemia. *Blood* 1984; 63: 789–799.
2. Hasford J, Pffirman M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukaemia treated with interferon alfa. *J Natl Cancer Inst* 1998; 90: 850–858.
3. Silver RT, Woolf SH, Hehlmann R et al. An evidence-based analysis of the effect of Busulfan, Hydroxyurea, Interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukaemia: Developed for the American Society of Hematology. *Blood* 1999; 94: 1517–1536.
4. Enright H, McGlave P. Chronic myelogenous leukaemia. In Hoffman R, Benz EJ, Shattil SJ (eds): *Hematology: Basic Principles and Practice*. Philadelphia: Churchill Livingstone 2000.
5. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. *Blood* 1990; 76: 2462–2465.
6. O’Brien SG, Guilhot F, Larson RA et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. *N Engl J Med* 2003; 348: 994–1004.

Coordinating authors for the ESMO Guidelines Task Force: B. Simons-son¹, O. Kloeke² & R. A. Stahel³

¹Invited author, Dept. Hematology, University Hospital, Uppsala, Sweden;

²Assigned task force member, Elisabeth Krankenhaus GmbH, Abt.

Onkologie/Hämatologie, Röntgenstrasse 10, 45 661 Recklinghausen,

Germany; ³Assigned task force member, Div. of Oncology, University Hospital, Rämistr. 100, CH-8091 Zürich, Switzerland

Approved by the ESMO Guidelines Task Force: August 2003, last update December 2004.

Correspondence to:

ESMO Guidelines Task Force

ESMO Head Office

Via La Santa 7

CH-6962 Lugano

Switzerland